Craig Hallum Analysts Give CareDx (NASDAQ:CDNA) a $48.00 Price Target

Craig Hallum set a $48.00 target price on CareDx (NASDAQ:CDNA) in a report released on Thursday morning, The Fly reports. The firm currently has a positive rating on the stock.

Several other equities analysts also recently commented on CDNA. Zacks Investment Research downgraded shares of Farmers & Merchants Bancorp, Inc. (OH) from a hold rating to a strong sell rating in a report on Thursday, May 9th. TheStreet downgraded shares of ZovioInc . from a c- rating to a d rating in a report on Thursday, May 23rd. Piper Jaffray Companies upped their price objective on shares of Beigene to $180.00 and gave the company an overweight rating in a report on Thursday, May 9th. Raymond James reissued an outperform rating and issued a C$28.00 target price on shares of Wheaton Precious Metals in a research report on Friday, March 22nd. Finally, BidaskClub cut shares of Xencor from a sell rating to a strong sell rating in a research report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average price target of $41.50.

NASDAQ:CDNA opened at $38.33 on Thursday. CareDx has a one year low of $11.85 and a one year high of $41.27. The company has a fifty day moving average of $35.68.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). CareDx had a negative net margin of 51.21% and a negative return on equity of 52.93%. The company had revenue of $25.98 million during the quarter, compared to analyst estimates of $24.27 million. Equities research analysts predict that CareDx will post -0.53 EPS for the current year.

In other news, insider Sasha King sold 1,250 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $29.50, for a total value of $36,875.00. Following the completion of the sale, the insider now owns 77,427 shares of the company’s stock, valued at $2,284,096.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William A. Hagstrom sold 15,000 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $32.35, for a total transaction of $485,250.00. Following the completion of the sale, the director now directly owns 25,272 shares of the company’s stock, valued at approximately $817,549.20. The disclosure for this sale can be found here. In the last three months, insiders sold 188,430 shares of company stock valued at $6,410,528. 3.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in CareDx by 7.0% in the fourth quarter. BlackRock Inc. now owns 2,491,800 shares of the company’s stock valued at $62,644,000 after purchasing an additional 162,939 shares during the period. Bank of New York Mellon Corp lifted its position in CareDx by 2.2% in the fourth quarter. Bank of New York Mellon Corp now owns 210,653 shares of the company’s stock valued at $5,295,000 after purchasing an additional 4,468 shares during the period. Northern Trust Corp lifted its position in CareDx by 6.0% in the fourth quarter. Northern Trust Corp now owns 439,231 shares of the company’s stock valued at $11,042,000 after purchasing an additional 24,677 shares during the period. Great West Life Assurance Co. Can acquired a new stake in CareDx in the fourth quarter valued at about $81,000. Finally, Geode Capital Management LLC lifted its position in CareDx by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 399,668 shares of the company’s stock valued at $10,047,000 after purchasing an additional 42,944 shares during the period. 88.75% of the stock is owned by institutional investors and hedge funds.

About CareDx

CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

See Also: Options Trading – Understanding Strike Price

The Fly

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.